Q4 2024 Stevanato Group SpA Earnings Call Transcript
Key Points
- Stevanato Group SpA (STVN) reported a 2% revenue growth for 2024, driven by a 6% increase in the Biopharmaceutical and Diagnostic Solutions segment.
- High-value solutions, including syringes, saw a 15% increase, representing 38% of total company revenue for 2024.
- Revenue from injectable biologics increased by 24% year over year, indicating strong demand in this segment.
- The company achieved significant milestones with its Fishers, Indiana facility generating its first commercial revenue and the Latina project in Italy turning profitable.
- Stevanato Group SpA (STVN) is strategically positioned to capitalize on the growing demand for biologic treatments and self-administrative medicines.
- The Engineering segment experienced a 7% decline in revenue, impacting overall company performance.
- There was a 34% decline in revenue related to bulk and EZ-fill vials due to industry-wide vial destocking.
- Gross profit margin for the fourth quarter of 2024 declined by 210 basis points to 29.7%, affected by vial destocking and underutilization of vial lines.
- The new manufacturing plants in Fishers and Latina are expected to be dilutive to gross profit margin in the near term.
- Free cash flow remained negative at EUR148.5 million for fiscal 2024, although it showed improvement from the previous year.
Good afternoon. This is the Chorus Call conference operator. Welcome, and thank you for joining the Stevanato Group fourth-quarter and year-end 2024 conference call. (Operator Instructions)
At this time, I would like to turn the conference over to Ms. Lisa Miles, Senior Vice President, Investor Relations. Please go ahead, madam.
Good morning, and thank you for joining us. With me today is Franco Stevanato, Chairman and Chief Executive Officer; and Marco Dal Lago, Chief Financial Officer. You can find a presentation to accompany today's results on the Investor Relations page of our website, which can be located under the Financial Results tab.
As a reminder, some statements being made today will be forward-looking in nature and only predictions. Actual events and results may differ materially as a result of the risks we face, including those discussed in Item 3D entitled Risk Factors in the company's most recent annual report on Form 20-F filed with the SEC.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
